Hims & Hers Health Stock Crashes After Earnings: Is Now the Time to Buy?
What Hims & Hers Health Investors Missed Before The Fall
Hims & Hers Stock Just Plummeted 17%. Is the Stock a Buy Ahead of a Peptide Push?
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Hims & Hers Health, Inc. 2026 Q3 - Results - Earnings Call Presentation
Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off
Hims & Hers Climbs 6% Despite Five States Joining FTC Suit; Eli Lilly Dips, Novo Nordisk Holds Steady
FTC Widens Its Hims & Hers Suit as Five States Join Over Privacy and Billing
Hims & Hers: Three Big Sacrifices
Hims & Hers Faces A ‘Transition Year’ Amid Increasing AI Investments, Says KeyBanc – Expects Lower Pricing To Weigh On FY2027-2028 Earnings Outlook
KeyBanc Waits for a Growth Inflection at Hims & Hers
Hims & Hers Week in Review: Q3 Miss, Weak Q4 Outlook, Huberman Joins Board
Hims & Hers Has Lost 53% of Its Value in a Year. Canaccord Still Sees $40
Hims & Hers (HIMS) Stock Price Faces Q3 Results Margin Reckoning
HIMS Q3 Earnings Call Highlights Marketing Reset and Margin Pressure
Why Is Hims & Hers Health (HIMS) Bringing Andrew Huberman Onto Its Board?
Hims & Hers Stocks Plunge 15.37% as Margin Squeeze Forces EBITDA Guidance Cut
Hims & Hers Drops 18% as Wall Street Loses Patience
Hims & Hers Celebrated Its Eli Lilly Deal, Then Lost a Quarter of Its Value in a Week
Five States Join FTC Lawsuit Alleging Hims and Hers Engaged in Deceptive and Unlawful Privacy Practices
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.